TRCT
NPCE icon

Tower Research Capital (TRC)’s Neuropace NPCE Stock Holding History

Tower Research Capital (TRC)’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.8K Buy
1,499
+480
+47% +$7.72K ﹤0.01% 3395
2026
Q1 		$13.4K Sell
1,019
-1,496
-59% -$22.4K ﹤0.01% 3746
2025
Q4 		$38.8K Buy
2,515
+578
+30% +$7.73K ﹤0.01% 2619
2025
Q3 		$20K Sell
1,937
-770
-28% -$7.26K ﹤0.01% 3312
2025
Q2 		$30.2K Buy
2,707
+1,946
+256% +$24.3K ﹤0.01% 3395
2025
Q1 		$9.35K Sell
761
-379
-33% -$4.74K ﹤0.01% 3791
2024
Q4 		$12.8K Sell
1,140
-63
-5% -$548 ﹤0.01% 3587
2024
Q3 		$8.38K Sell
1,203
-3,208
-73% -$23.5K ﹤0.01% 3966
2024
Q2 		$33.3K Buy
4,411
+648
+17% +$6.54K ﹤0.01% 3405
2024
Q1 		$49.7K Buy
3,763
+3,511
+1,393% +$50.1K ﹤0.01% 2280
2023
Q4 		$2.6K Buy
+252
New +$2.01K ﹤0.01% 5191
2023
Q3 		– Sell
-90
Closed -$404 – 6143
2023
Q2 		$404 Sell
90
-694
-89% -$3.14K ﹤0.01% 5657
2023
Q1 		$4K Sell
784
-4,928
-86% -$18.9K ﹤0.01% 5095
2022
Q4 		$9K Buy
5,712
+752
+15% +$1.67K ﹤0.01% 4224
2022
Q3 		$19K Buy
+4,960
New +$23.9K ﹤0.01% 3978
2022
Q2 		– Sell
-1,632
Closed -$13K – 6382
2022
Q1 		$13K Buy
1,632
+506
+45% +$4.37K ﹤0.01% 3988
2021
Q4 		$11K Buy
1,126
+569
+102% +$7.39K ﹤0.01% 4435
2021
Q3 		$9K Sell
557
-786
-59% -$16.5K ﹤0.01% 4453
2021
Q2 		$32K Buy
+1,343
New +$31.2K ﹤0.01% 3426

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Tower Research Capital (TRC)'s NPCE Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Neuropace (NPCE) stake by 47% in Q2 2026, buying an estimated $7.72K and bringing the position to 1,499 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3395.

Tower Research Capital (TRC) first reported a position in NPCE in Q2 2021 and has held it in 19 quarters since. The position peaked at $49.7K in Q1 2024. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Tower Research Capital (TRC) held 1,499 shares of Neuropace worth $23.8K as of Q2 2026.
  • Tower Research Capital (TRC) bought 480 Neuropace shares in Q2 2026, an estimated $7.72K.
  • Neuropace made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3395 holding.
  • Tower Research Capital (TRC) first reported a position in Neuropace in Q2 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Neuropace position peaked at $49.7K in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.